Next Issue
Volume 12, November
Previous Issue
Volume 11, October
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Hematol. Rep., Volume 12, Issue 1 (May 2020) – 6 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
3 pages, 372 KiB  
Case Report
The Curious Case of Hemoglobin DC Disease Masquerading as Sickle Cell Anemia
Hematol. Rep. 2020, 12(1), 8519; https://doi.org/10.4081/hr.2020.8519 - 22 May 2020
Cited by 1 | Viewed by 554
Abstract
Hemoglobin D is a relatively rare disease first reported in 1951. We present the first reported case of Hemoglobin DC disease. This is a case of a Hemoglobinopathy with DC disease in a woman with a previous diagnosis of Hemoglobin SC disease. A [...] Read more.
Hemoglobin D is a relatively rare disease first reported in 1951. We present the first reported case of Hemoglobin DC disease. This is a case of a Hemoglobinopathy with DC disease in a woman with a previous diagnosis of Hemoglobin SC disease. A 19-year-old woman presented to the Adult Hematology clinic at a tertiary care hospital in Northwest Louisiana for transition of care from Pediatric Hematology for a diagnosis of Hemoglobin SC disease diagnosed at the age 4. Historical data suggested no avascular necrosis, acute chest syndrome, and very few episodes of pain crisis. She has never taken hydroxyurea. Laboratory work showed persistently normal hemoglobin and white blood cell counts. All sickle cell preparations in the past were negative. Computerized tomography scan of the abdomen was reviewed and showed a spleen grossly normal in size and appearance. Given the incongruent clinical picture for sickle cell disease, repeat hemoglobinopathy evaluation with Capillary electrophoresis and confirmatory acid electrophoresis (to differentiate hemoglobins that co-migrate with Hemoglobin S) showed a probable double heterozygote for Hemoglobin D and C with suspected coexistent alpha thalassemia minor based on red blood cell indices. This case confirms the importance of the required confirmatory method to ensure a correct diagnosis since a misdiagnosis can lead to numerous adverse clinical or psychological effects for patients. Full article
4 pages, 569 KiB  
Case Report
Brentuximab Vedotin for Refractory Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in Leukemic Phase with RUNX3 Overexpression
Hematol. Rep. 2020, 12(1), 8368; https://doi.org/10.4081/hr.2020.8368 - 15 May 2020
Cited by 3 | Viewed by 473
Abstract
Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in leukemic phase, characterized [...] Read more.
Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in leukemic phase, characterized by an extremely poor prognosis. Lymphoma cells in this case showed chromosomal translocation 1p36.1- encoded RUNX3 and overexpression of its protein. She was refractory to CHOP and salvage chemotherapy. Fortunately, she achieved complete remission with three cycles of Brentuximab vedotin (BV) and underwent umbilical cord blood transplantation. However, she died due to treatment-related mortality on day 129. The autopsy findings showed no lymphoma cells. Treatment strategy for ALK-ALCL is controversial, but the efficacy of BV in CD30-positive peripheral T-cell lymphoma not only as salvage regimens, but also in first line, has been reported in recent years. BV may be an effective option for ALK-ALCL in leukemic phase. Full article
3 pages, 402 KiB  
Case Report
Successful Allogeneic Bone Marrow Transplantation Using Immunosuppressive Conditioning Regimen for a Patient with Red Blood Cell Transfusion-Dependent Pyruvate Kinase Deficiency Anemia
Hematol. Rep. 2020, 12(1), 8305; https://doi.org/10.4081/hr.2020.8305 - 15 May 2020
Cited by 3 | Viewed by 491
Abstract
Pyruvate kinase deficiency (PKD) is the rare glycolytic enzyme defect causing hemolytic anemia. Treatments are mainly red cell transfusion and/or splenectomy, leading to iron overload. Allogeneic bone marrow transplantation (BMT) is alternatively curative treatment for severe PKD. The intensity of conditioning is often [...] Read more.
Pyruvate kinase deficiency (PKD) is the rare glycolytic enzyme defect causing hemolytic anemia. Treatments are mainly red cell transfusion and/or splenectomy, leading to iron overload. Allogeneic bone marrow transplantation (BMT) is alternatively curative treatment for severe PKD. The intensity of conditioning is often controversial because of higher risk of graft failure and organ damage. Here, we present a transfusion-dependent PKD patient undergoing BMT from an HLA-identical sibling using intensively immunosuppressive conditioning regimen. This report suggests that BMT using immunosuppressive conditioning regimen may be a feasible and effective treatment for patients with severe PKD with iron overload. We suggest the timing of the transplantation at an earlier age in severe PKD predicted from gene mutation is preferred before cumulative damage of transfusion. Full article
6 pages, 4311 KiB  
Article
Immunoistochemical Expression of PD-1 and PD-L1 in Bone Marrow Biopsies of Patients with Acute Myeloid Leukemia
Hematol. Rep. 2020, 12(1), 8211; https://doi.org/10.4081/hr.2020.8211 - 07 May 2020
Cited by 1 | Viewed by 387
Abstract
Haematological and non-haematological malignancies are able to escape the host immune by the capacity to hijack the immune check-points [...] Full article
9 pages, 751 KiB  
Article
Effect of Antiepileptic Drugs on Plasma Fibrinogen Level
Hematol. Rep. 2020, 12(1), 7952; https://doi.org/10.4081/hr.2020.7952 - 07 May 2020
Cited by 1 | Viewed by 382
Abstract
Background: Childhood epilepsy is one of the most common neurological disorders in pediatrics. The prevalence of active epilepsy is 5–8 per 1000 population in developed countries and 10 per 1000 population in developing nations. There is a significant relationship between epilepsy and cognitive [...] Read more.
Background: Childhood epilepsy is one of the most common neurological disorders in pediatrics. The prevalence of active epilepsy is 5–8 per 1000 population in developed countries and 10 per 1000 population in developing nations. There is a significant relationship between epilepsy and cognitive deficits. Aim of study: prospective study to evaluate the effect of the most commonly used anti-epileptics drugs on plasma fibrinogen level. Patient and methods: 100 newly diagnosed patients (2 months to 15 years old) selected from Outpatient Clinic of Neurology attending Mansoura University Children’s Hospital for plasma fibrinogen level evaluation by taking basal sample and second sample after six months after the basal one. Results: This study showed that, significant positive correlation between plasma fibrinogen level and the use of antiepileptic drugs. Conclusions: epileptic patient should be closely monitored during Antiepileptic drugs treatment and prior to surgical procedures as they can affect plasma fibrinogen level and coagulation profile. Full article
5 pages, 387 KiB  
Article
Comparison of Bortezomib-Cyclophosphamide-Dexamethasone versus Bortezomib-Dexamethasone Based Regimens in Newly Diagnosed Multiple Myeloma Patients
Hematol. Rep. 2020, 12(1), 8267; https://doi.org/10.4081/hr.2020.8267 - 06 May 2020
Cited by 2 | Viewed by 341
Abstract
The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8–10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regimen [...] Read more.
The treatment landscape and clinical outcome of multiple myeloma (MM) patients have changed in the last decades, with an improved median survival of 8–10 years. This study aimed to evaluate the bortezomib, cyclophosphamide and dexamethasone (VCD) regimen versus bortezomib and dexamethasone (VD) regimen in patients with newly diagnosed MM. This study has been performed in a retrospective manner. One hundred and three patients with newly diagnosed MM who received chemotherapy at our tertiary care center between the years of 2009 and 2018 were evaluated. A total of 103 patients were included. The 5-year overall survival (OS) for patients who received VD regimen and patients who received VCD regimen were 75% and 83%, respectively. The OS for VD patients was 113.1 ± 12.5 versus 122.2 ± 9.5 months for VCD patients with no statistically significant difference (p = 0.47). The 5-year PFS (progression free survival) for patients who received VD regimen and patients who received VCD regimen were 66% and 75%, respectively. The PFS for VCD patients was higher than the PFS for VD patients (67.1 ± 7.4 versus 97.7 ± 13.4 months), but no statistically significant difference was observed (p = 0.59). Relapse rate (p = 0.002) and mortality rate (p = 0.01) were higher in VD group than VCD group and they were statistically significant. The OS and PFS were clinically longer in patients receiving VCD regimen than in patients receiving VD regimen, although not statistically significant. Cyclophosphamide should be given to patients at physician discretion and depending on patient’s frailty function. Full article
Previous Issue
Next Issue
Back to TopTop